To review the experience with the operative treatment of tertiary hyperparathyroidism (TH) from a single renal transplant center.
Objective
To review the experience with the operative treatment of tertiary hyperparathyroidism (TH) from a single renal transplant center.
Summary Background Data
Most patients with chronic renal failure show evidence of secondary hyperparathyroidism by the time maintenance hemodialysis begins. Persistent secondary hyperparathyroidism (i.e., TH) requiring surgical intervention is uncommon in the authors' experience.
Methods
Charts of patients who underwent parathyroidectomy for TH were reviewed retrospectively. Information obtained included demographics, laboratory data, symptoms, operative procedure (including morbidity and mortality rates), and pathology. Comparisons of demographic data and allograft survival were made between the transplant population as a whole and a matched cohort group of patients.
Results
Thirty-eight patients from 4344 renal transplant procedures during a 29-year period required parathyroidectomy for TH. All patients had hypercalcemia; 20 were asymptomatic and 18 had varying symptoms. Mean time from renal transplantation to parathyroidectomy was 997 ± 184 days, with a mean preoperative calcium level of 12.2 ± 0.14 mg/dl. Total parathyroidectomy with parathyroid autograft was performed in 26 of 34 primary procedures. There were no deaths. The operative morbidity rate was 6% (wound separation and vocal cord hemiparesis, one each). Pathology was reported in all patients and recently reviewed in 28 patients. Twenty-four had diffuse hyperplasia and nine had nodular hyperplasia; one had an adenoma. Parathyroid glands diagnosed as nodular hyperplasia were significantly larger by total mass than those with diffuse hyperplasia. Comparison of allograft survival between the study group and a matched cohort group of patients revealed no difference in long-term graft survival.
Conclusions
Operative intervention is recommended in patients with an asymptomatic increase in serum calcium to >12.0 mg/dl persisting for >1 year after the transplant, acute hypercalcemia (calcium >12.5 mg/dl) in the immediate posttransplant period, and symptomatic hypercalcemia.
It has been estimated that as many as 90% of patients with chronic renal failure develop evidence of secondary hyperparathyroidism by the time maintenance hemodialysis relation between renal disease and parathyroid hyperplasia is thought to result from abnormalities in the tubular absorption of phosphate and an associated decrease in serum calcium. In addition, renal failure is associated with a decreased conversion of 25-hydroxycholecalciferol to 1,25hydroxycholecalciferol in the kidney, resulting in a decrease in intestinal absorption of calcium. These combined effects result in a decreased serum calcium level, thereby providing a strong and persistent stimulus for the release of parathy-roid hormone (PTH) with resultant parathyroid hyperplasia. The natural history of secondary hyperparathyroidism has been described elsewhere3 and became more prevalent after the advent of hemodialysis. Despite improvements in the medical management of patients with chronic renal insufficiency, some patients with secondary hyperparathyroidism continue to develop progressive bone disease, manifested by osteitis fibrosa cystica and soft-tissue calcification. This led Stanbury et al.4 to recommend subtotal parathyroidectomy to reduce gland mass, a point confirmed clinically by Wilson et al. in 1971.5 It was commonly believed that after restoration of normal renal function with successful transplantation, the hyperplastic glands would involute and return to a normal functional state. However, after renal transplantation, some patients continue to have hyperparathyroidism. St. Goar recognized this disease entity and termed it "tertiary hyperparathyroidism."6 In 1964, McPhaul et al.7 published the first successful management of a patient with this disease using subtotal parathyroidectomy. Early reports in the transplant literature cited multiple detrimental effects of hypercalcemia on graft function and recommended prompt, aggressive surgical treatment of patients with posttransplant hyperparathyroidism.8 Other publications found that posttransplant hypercalcemia, primarily occurring early after the transplant, generally resolved within 1 year after successful renal transplantation.9 The reported incidence of hypercalcemia after renal transplantation ranged from 8.5% to 53%. Data from large clinical series noted that hypercalcemia occurred in approximately 30% of all patients undergoing renal transplantation. However, of the patients who developed hypercalcemia, few required operative reduction of parathyroid gland mass as definitive treatment.
This review provides an in-depth analysis of 38 patients who required operative intervention for treatment of tertiary hyperparathyroidism (TH).
METHODS
Between May 1968 and June 30, 1997, at the University of Alabama at Birmingham, 4344 renal transplants (2908 cadaveric and 1436 living donor) were performed in 3909 patients. Of these 3909 patients, 38 required parathyroidectomy for TH. One additional patient in whom we performed parathyroidectomy was transplanted elsewhere and excluded from the analysis. Of these 38 patients, 34 had their parathyroidectomy performed at our institution; the other 4 had the procedure performed elsewhere. Charts from all patients were reviewed retrospectively and included laboratory data before the transplant and the parathyroidectomy. Information obtained included demographic data; serum calcium and phosphorus; type and duration of dialysis; operative technique; pathologic size, weight, and histology of parathyroid glands; and need for calcium supplementation after parathyroidectomy.
For survival and demographic comparisons, two control groups were chosen. The first control group comprised 899 patients closely matched to the study group for year of transplant, age, sex, race, and number of transplants and was used for comparison of graft survival. There were no differences between the groups for HLA A+B match or immunosuppressive protocol. In an attempt to control for patient selectivity based on survival in the study group, patients chosen for the control group required a functioning graft for '24 months. The other control group consisted of the entire transplant population not including the study group and was used primarily for demographic comparison.
Immunosuppressive regimens used at our institution can be divided into four eras. The first era included patients undergoing transplantation between May 8, 1968, and 1983 . These patients received azathioprine and prednisone, with occasional use of antithymocyte globulin. The second era was from 1984 to 1986, with patients receiving cyclosporine, azathioprine, and prednisone (triple therapy), and occasionally antilymphocyte globulin. The third era, from 1987 through July 1995, included the standard immunosuppressive regimen consisting of azathioprine, prednisone, cyclosporine, and various antilymphocyte preparations, including OKT3 (quadruple therapy) in patients receiving cadaveric kidneys. Only a few patients receiving living donor kidneys received OKT3. Since August 1995, mycophenolate mofetil has replaced azathioprine in all patients and quadruple therapy has been used only for cadaveric recipients. In the study population undergoing parathyroidectomy, 13 patients (34%) were treated with azathioprine and prednisone, 17 (45%) with triple therapy, and 7 (18%) with quadruple therapy including azathioprine. One additional patient (3%) received quadruple therapy with mycophenolate mofetil instead of azathioprine.
Information regarding gland size and weight was obtained from the surgical pathology reports. Specimens from 28 patients were reviewed. Cell composition in the individual glands was calculated using a 10 X 10 grid for small glands. In larger glands, the individual counts were performed using 200 to 400 individual counts. Only cell composition for the actual gland was calculated. Counting error in individual measurements was estimated to be <7%, assuming Poisson 
RESULTS

Incidence
Four thousand three hundred forty-four renal transplant procedures in 3909 patients were performed at the University of Alabama at Birmingham Transplant Center between May 1968 and June 1997. Thirty-eight patients eventually required parathyroidectomy for TH, an overall incidence per transplant procedure of 0.87%. There was an incidence of 1.3% in white recipients and 0.28% in black recipients (Table 1) . On a per-patient basis (some patients received more than one allograft), the overall incidence was 0.97% (38 of 3909), 1.45% (33 of 2277) for white recipients and 0.31% (5 of 1617) for black recipients.
Demographics
Patient characteristics are summarized in Table 2 . The mean age was 39.5 years (range, 22 to 60). There was a nearly even distribution of men and women (18:20) . Most patients (n = 27) in the study group received allografts from cadaveric donors, and most (n = 32) were recipients of primary transplants. The primary disease was glomerulonephritis (n = 12), unknown (n = 7), tubulointerstitial disease (n = 6), vascular (n = 5), hereditary (n = 5), diabetes (n = 1), collagen-vascular (n = 1), and acquired (n = 1). Comparisons between the study group and the control transplant population revealed no statistical differences with reference to age (p = 0.18), sex (p = 0.06), graft origin (p = 0.59), or primary versus other transplant (p = 0.58). However, a statistically significant difference was noted with regard to race: there were fewer black patients in the study group (5 of 38, 13%) than in the transplant population (1790 of 4344, 41%) (p < 0.01). Thirty-two of the 38 patients received hemodialysis for a mean duration of 37.39 months (range, 0.5 to 144); 8 received chronic ambulatory peritoneal dialysis for a mean period of 15 months (range, 1 to 36). Two patients were started on chronic ambulatory peritoneal dialysis but ultimately required hemodialysis. The difference in duration of dialysis between these two groups was not statistically significant. Because dialysis data were unavailable for the entire transplant population, a comparison between the study group and the control groups was impossible.
Signs and Symptoms
Patients' signs and symptoms are summarized in Table 3 . All patients had hypercalcemia (normal serum calcium <10.2 mg/dl). Five patients (13%) had early, severe posttransplant hypercalcemia necessitating surgery within the first 90 days after transplantation. Twenty patients (53%) had hypercalcemia without other signs or symptoms. The remaining 13 patients had an array of symptoms including bone pain (n = 9), quadriceps muscle weakness (n = 8), arthralgias (n = 5), nephrolithiasis (n = 3), and central nervous system abnormalities (n = 2). Only one patient had important arterial calcification. Several patients had more than one symptom.
All patients had hypercalcemia before parathyroidectomy (see Table 3 ). Seventeen patients (45%) were hypercalcemic before transplantation; the remaining patients developed hypercalcemia within the first year. A mean serum calcium level of 12.20 ± 0.14 mg/dl was present before parathyroidectomy. The mean serum calcium level was 11.81 ± 0.17 mg/dl (range, 10.8 to 13.6) in symptomatic patients and 12.56 ± 0.20 mg/dl in patients without symptoms (p = NS). In the five patients with severe posttransplant hypercalcemia, the mean serum calcium level was 13.94 ± 0.22 mg/dl ( Table 4 ). All patients had elevated preoperative serum parathyroid levels using several different assays.
Surgical Treatment
The mean time to parathyroidectomy after transplantation was 997 ± 184 days (range, 25 to 4548) ( Table 5 ). Thirtyfour patients had the procedure at our institution; the other four had it done elsewhere. Two patients were operated on at our hospital for persistent hypercalcemia. The operative technique of choice in 26 of the 34 procedures at our hospital included total parathyroidectomy with parathyroid autograft, as described. 3 The estimated autograft weight was 50 to 60 mg in the early experience, which was increased to 80 to 100 mg later. The autograft was placed in the sternocleidomastoid muscle in all patients. In one patient, only three glands could be identified; all three were resected, with a portion of one gland reimplanted as an autograft. Subtotal parathyroidectomy was performed in seven patients, and a two-gland resection was performed on a patient with a pathologic diagnosis of parathyroid adenoma. Two patients underwent reoperation for persistent hypercalcemia (one primary procedure performed at our hospital and one at another hospital). One of these two patients had a subtotal parathyroidectomy performed initially, with 2.5 glands removed. The fourth gland could not be identified at the initial procedure. This patient remained hypercalcemic after parathyroid surgery and ultimately required reoperation with removal of the remaining gland. An additional patient had previous removal of two glands at another hospital. At reoperation, only one gland was identified and removed, with a portion of this parathyroid gland reimplanted as an autograft. After surgery the patient was normocalcemic.
Of the 36 procedures performed at our hospital, operative morbidity occurred in 2 (6%), a recurrent laryngeal nerve injury in one patient and a wound separation in another. There were no operative deaths. Average length of hospital stay was 5.42 ± 0.54 days. Patients were maintained on an intravenous calcium infusion during the immediate postoperative period before conversion to oral calcium supplementation before discharge. 
Pathology
Surgical pathology reports of parathyroid tissue removed were reviewed in all procedures performed at our hospital. Thirty-three of the 34 patients had the diagnosis of parathyroid hyperplasia; the other patient had a benign adenoma. Parathyroid gland weight was available in 24 patients, and data regarding gland size were reported in 31 patients ( Table 6 ).
Pathologic slides of parathyroid tissue in 28 cases were reviewed for this study. Glands were composed of diffusely hyperplastic tissue with elements of chief cells, oxyphil cells, and water clear cells in varying distribution ( Table 7) . In 23 patients, chief cell hyperplasia was present. In nine cases, there was evidence of nodular hyperplasia. The nodules consisted of chief cells in five patients and oxyphil cells in the remaining four. The weight of removed parathyroid glands was significantly greater in patients with nodular hyperplasia than in those with diffuse hyperplastic change (p < 0.01) (see Table 7 ). One patient had an adenoma in a solitary gland; another gland removed from the same patient was histologically normal.
RESULTS
The final date of follow-up was September 30, 1997. No patients were lost to follow-up. Of the 38 patients, 27 were alive; 11 had died for reasons unrelated to hyperparathyroidism. Twenty-two of the 27 living patients maintained good renal allograft function and 5 developed chronic rejection; 4 of these 5 patients subsequently lost their grafts because of chronic rejection. The mean serum calcium level 1 year after parathyroidectomy was 9.10 ± 10 mg/dl (range, 6.9 to 1 1.3). Three of the 38 patients had documented hypoparathyroidism after their parathyroidectomy and required longterm calcium supplementation. The intact PTH level was <15 pg/ml. These three patients all underwent total parathyroidectomy with autograft, with estimated parathyroid replacement of 30 to 40 mg.
Symptomatic improvement was reported in almost all patients, with resolution of bone pain in 10 to 14 days. Muscle weakness and central nervous system disturbances improved during a period of several months. The results were less gratifying in patients who had arthralgias before surgery: only two of five patients achieved resolution of symptoms. However, two of the three patients with arthralgia did not demonstrate important resolution of pain, and both had a history of gouty arthritis.
Of the three patients who underwent parathyroidectomy for nephrolithiasis, two continued to develop stones after parathyroid surgery. One of these patients had a ureteroureterostomy performed; the other underwent a more complex ureteral reconstruction. In both patients, stones were noted to occur on sutures in the ureter and were not thought to originate from the kidney. These two patients were normocalcemic.
Comparisons between allograft survival in the study group and the control group are shown in Figure 1 . Allograft survival was not statistically significant between the two groups (p = 0.14).
DISCUSSION
Nearly all patients with chronic renal failure exhibit some degree of secondary hyperparathyroidism, defined as parathyroid hyperplasia and elevated serum PTH levels. It was originally believed that restoration of renal function by renal transplantation would result in involution of hyperplastic parathyroid tissue and correction of hyperparathyroidism. In most instances, the serum calcium level returns to normal within 1 year after kidney transplantation. However, increased PTH levels may persist for years after renal transplantation.12 '13 The reasons for the persistence of hyperparathyroidism are unknown but may be related to the duration of renal failure and dialysis before transplantation. Although serum PTH levels are frequently elevated in patients after transplantation, only a few have clinical signs and symptoms of hyperparathyroidism. The natural history of hyperparathyroidism with persistent hypercalcemia after renal transplantation documents that approximately 30% of posttransplant patients have posttransplant hypercalcemia.13,14 One third of these patients maintain persistently elevated serum calcium levels, and even fewer ultimately require operative intervention. Thus, TH is uncommon.
The natural history of serum calcium levels after renal transplantation can be divided into four groups: patients with normal serum calcium levels; patients with hypercalcemia in the immediate posttransplant course with return to normal in 12 to 15 months; patients with prolonged hypercalcemia >1 year after transplantation; and patients with normocalcemia in the early posttransplant course and progression to hypercalcemia months or years later.
In our experience, 0.97% (38 of 3909) of our renal transplant patients required parathyroidectomy for TH; this is slightly less than reported by others (1.3% to 2.9%). [14] [15] [16] [17] In the black transplant population, only 5 of 1617 patients (0.31%) required parathyroidectomy. This may explain the lower overall incidence reported in this study compared with other transplant centers that have fewer black recipients in their transplant population. Black recipients made up 41% of our transplant population, but only 13% of our study group was black. The reasons for this racial difference are unclear. A predisposition to longer pretransplant dialysis times has been noted in patients with TH.12'14 The length of dialysis in this group of patients was 37.7 months (range, 0.5 to 144); however, data regarding dialysis duration were unavailable for comparison with the entire transplant population. Nonetheless, the dialysis duration in this set of patients exceeded that reported in other studies where trends toward longer dialysis times were noted in those ultimately requiring parathyroidectomy. However, the lower incidence of hyperparathyroidism requiring parathyroidectomy in the black transplant recipients, coupled with longer wait times18 and therefore longer dialysis times, suggests that factors other than duration of dialysis are involved in the etiology of TH.
Data from this series of patients were similar to other studies with regard to pathology of parathyroid glands.19
Review of the pathology in these patients revealed most tissue to be diffusely hyperplastic, involving four glands. Chief cells were the predominant cell type, although occasionally oxyphil cells were the major cellular component (see Table 6 ). Nodular hyperplasia was identified in 9 of the 28 cases examined. These glands were noted to be significantly larger than diffusely hyperplastic glands (p = 0.002).
The benign adenoma with single-gland involvement in one patient was not related to the patient's underlying chronic renal disease.
All the patients in this study had hypercalcemia at the time of parathyroidectomy, and most were operated on for persistently elevated serum calcium levels without associated symptoms. The remaining patients displayed a variety of symptoms that paralleled previously published reports.14,20-23 Development of symptoms did not necessarily correlate with the level of serum calcium. Bone pain, particularly of the vertebral column and lower extremities, was seen in 24% of patients. This pain was frequently more severe at night. Quadriceps weakness was also frequently observed (21%) and was especially apparent when the patient rose from a sitting position or when climbing stairs. Bone pain was relieved within a few days of parathyroidectomy; quadriceps weakness improved after several months.
Nephrolithiasis is an uncommon complication of renal transplantation,2425 even in the presence of hypercalcemia.14 '20'26'27 In this series, two of the three patients with renal calculi had undergone complex urinary reconstruction; the origin of the stones was thought to be from the suture line.
The clinical impact of hypercalcemia on renal allograft function remains unclear. Previous reports suggested that severe elevation of the serum calcium level has a detrimental effect on renal function.89 In our series, five patients required urgent parathyroidectomy within 90 days after transplantation because of severe hypercalcemia (mean serum calcium 13.94 ± 0.22 mg/dl). Three of the five patients developed mild to moderate elevations in serum creatinine concurrent with the increase in serum calcium. A decrease in serum calcium after parathyroidectomy noted in all patients was associated with a return of serum creatinine to baseline.
Patients requiring parathyroidectomy, when compared with a cohort group of renal transplant patients, showed no statistically significant difference with regard to allograft survival (see Fig. 1 ). This observation suggests that there is little or no effect on serum creatinine levels over time in patients with mild to moderate posttransplant hypercalcemia (serum calcium > 11.5 mg/ml). This experience has led to a conservative approach in renal transplant patients with hypercalcemia and TH because the great majority remain asymptomatic, have no obvious impairment of renal function, and will not require surgical intervention. Our recommendations for surgical intervention are in patients with: an asymptomatic increase in serum calcium to levels >12 mg/dl persisting for >1 year after the transplant, acute hypercalcemia (serum calcium >12.5 mg/dl) in the immediate posttransplant period, and symptomatic hypercalcemia. In our experience, total parathyroidectomy with autograft has proven to be a satisfactory procedure. However, adequate parathyroid autograft tissue should remain to avoid postoperative hypercalcemia. Subtotal parathyroidectomy is also an Ann. Surg. * June 1998 effective procedure, and the choice of operative technique should be left to the surgeon. Discussion COLIN G. THOMAS, JR. (Chapel Hill, North Carolina): President Wells, Secretary Copeland, Members, and Guests. Based upon a very rigorous and critical review of the manuscript, which I received well in advance, and after hearing the presentation, I am compelled to conclude that this is a very fine piece of work, and Dr. Diethelm and his colleagues fully deserve our congratulations. This is a remarkable experience and noteworthy in several respects.
With a data base of over 4000 transplant recipients, 29 years of observation, less than 1% of patients required parathyroidectomy for continuing hyperparathyroidism. The clinical results are excellent with minimal morbidity. Their recommendations are wellfounded and should be valuable to all of us in the management of these challenging problems. However, I do have a few questions.
The reasons for persistent hyperparathyroidism have been stated to be related to a variety of factors such as impaired renal graft function, autonomy of parathyroid function, persistence of high calcium set point for setting off the parathyroid insufficient calcitriol secretion. Do the authors have an opinion as to the mechanism that best explains the persistent hyper function of these parathyroid glands?
In the asymptomatic patient, a calcium level of 12 mg per dL constitutes an indication for parathyroidectomy. How is this figure derived? It is higher than that recommended at a recent NIH conference for patients with primary asymptomatic hyperparathyroidism. Yet, their patients with normal renal function might be considered to be in the same category.
Immunoparathyroid hormone levels were not mentioned as a factor influencing a decision for reoperation. With patients being on Prednisone and an elevated immunoparathyroid hormone level, are you not concemed about the continued loss of bone density?
Perhaps it should be monitored.
Eleven percent of the patients undergoing total parathyroidectomy developed permanent hypoparathyroidism. Does cryopreservation provide a mechanism for recovery? Or should subtotal parathyroidectomy be carried out more frequently? I commend to this audience the published article for serious thought and predict that, unlike the Magna Charta which is more frequently quoted than read, this paper will be read and widely quoted.
Thank you.
[Applause]
Operative Treatment of Tertiary Hyperparathyroidism 885 DR. SAMUEL A. WELLS, JR. (St. Louis, Missouri): I wanted to discuss this paper also, and I thought that it contained a great deal of useful information. I was interested in the one patient that you presented that had a parathyroid adenoma and wondered whether that patient and, perhaps, other patients, as we have seen occasionally, actually had primary hyperparathyroidism, developed renal disease and a subsequent, secondary hyperparathyroidism as a complication. These patients, when operated on, often have minimally elevated parathyroid glands, minimally elevated in size, except for the one large presumed parathyroid adenoma. I would be interested in knowing your thoughts about that one case. I, too, was concerned about the decision point of 12 mg per dL. John Potts, who is a mineral metabolism expert at the Massachusetts General Hospital chaired the committee on asymptomatic hyperparathyroidism at the NIH, and he did recommendor the committee dida lower point of intervention. These patients are at risk for bone disease, especially this group of patients who have preexisting bone disease. Are they placed at greater risk if you choose not to intervene surgically? I would be interested in knowing your thoughts about these two questions.
DR. JEFFREY D. KERBY (Closing Discussion): President Wells, Secretary Copeland, Members, and Guests. It is indeed an honor for me to be invited by Dr. Diethelm to close the discussion on this paper. I would like to thank Dr. Thomas and Dr. Wells for their comments and for their questions.
Dr. Thomas asked a number of questions, the first as to a mechanism for persistent hyperparathyroidism in these patients with normal renal function. Currently, we don't have a good answer for that question. We know that 30% of patients posttransplant develop hypercalcemia. Close to 60% to 70% of those patients resolve their hypercalcemia within the first year. And it is very difficult to predict which patients will resolve and which patients will not, which patients will develop symptoms long term and which patients will not. So I don't have a clear answer as far as a mechanism.
As far as how we derived the calcium level of 12.0 as our set point for recommending parathyroidectomy: There is some evidence that patients that have calcium levels over 12 do develop some of the metabolic complications of hypercalcemia, bone problems, pancreatitis, and some soft tissue calcification. We have followed patients with persistent borderline hypercalcemia who are asymptomatic for a number of years, and have found them not to have any of the complications. It is true that, certainly, this level is higher than some have recommended, and we should take a look at these patients that we are following long term to more closely examine this level.
As far as examining PTH levels in these patients, we have followed PTH levels in some of these patients. We used varying assays over the 29-year period of the study, and we found it very difficult to include this in our results.
There is some evidence that up to 50% of posttransplant patients have elevations of PTH without concurrent elevation of serum calcium, so we find it kind of difficult to use PTH levels as a means of determining when to suggest parathyroidectomy.
Three of the patients in our study were hyperparathyroid after their parathyroidectomy. The question was whether cryopreservation or a more liberal use of subtotal parathyroidectomy would be recommended. As Dr. Diethelm stated in the presentation, it had been our experience to put back about 30 mg to 60 mg of tissue
